e-therapeutics
Second agreement helps validate capabilitiesHutchison China MediTech
Carrying momentum into H219Bonesupport
All eyes on Q3 following a record Q2MaxCyte
Ideally placed to sustain growthMereo BioPharma
Accelerated approval path for NAVIScancell
Ground prepared for an important periodHutchison China MediTech
Secondary ADS offering trims CK Hutchison stakeBerGenBio
Private placement to support randomised Phase II trialsHutchison China MediTech
Surufatinib on track for potential 2020 China approvalHutchison China MediTech
Impressive data means SANET-ep trial stopped early